IPG Photonics (IPGP) investor relations material

Executive summary

• Second quarter 2026 revenue rose 11% year-over-year to $279 million, marking the third consecutive quarter of double-digit growth, driven by strong industrial and advanced solutions demand and growth in semiconductor sales.

• Bookings increased, maintaining a book-to-bill ratio above one for the third consecutive quarter, indicating sustained demand.

• Adjusted gross margin and adjusted EPS exceeded expectations, supported by cost management, tariff refunds, and strategic initiatives.

• Announced acquisition of Lumibird Medical to expand into higher-margin medical markets, expected to close in Q4 2026 and increase addressable market by $1 billion.

• Net income for Q2 2026 was $5.2 million, down from $6.6 million, primarily due to a $17.6 million impairment charge related to the planned sale of Belarus operations.

Financial highlights

• Total revenue was $278.6 million, up 11% year-over-year and 5% sequentially; six-month revenue up 14%.

• GAAP gross margin was 40.4%; adjusted gross margin was 40.7%, up 290bps year-over-year, aided by a $4.7 million tariff refund.

• Adjusted EBITDA reached $48.5 million, up 54% year-over-year and exceeding guidance.

• Adjusted EPS was $0.58, up 93% year-over-year; adjusted net income was $24.7 million.

• Cash and short-term investments totaled $871 million, with no debt.

Outlook and guidance

• Q3 2026 revenue expected between $265 million and $295 million; adjusted gross margin guidance is 37.5%-40.5%.

• Adjusted operating expenses projected at $92 million-$95 million; adjusted EPS expected in the $0.30-$0.60 range.

• Adjusted EBITDA guidance for Q3 is $35 million-$51 million.

• CapEx outlook for 2026 remains $90 million-$100 million, including major investments in Germany.

• Book-to-bill ratio above one, indicating robust demand.